On March 19th, Danish pharmaceutical giant Novo Nordisk announced an investment of approximately 4 billion yuan in Tianjin for the expansion project of sterile preparations. The reporter learned from the pharmaceutical company that investment will further enhance the company's production capacity in China to meet the future demand for innovative drugs in the Chinese market. Lian Maojun, member of the Standing Committee of the Tianjin Municipal Party Committee and Secretary of the Binhai New Area District Party Committee, expressed the hope that the company will accelerate the localization production of GLP-1 products and introduce more new products for treating diseases such as obesity. It is reported that the Tianjin production plant in China is one of Novo Nordisk's global strategic production bases, playing an important role in the global supply chain.